ArticleResearch (Washington, D.C.)2025
Forecasting the Global Burden of Peripheral Artery Disease from 2021 to 2050: A Population-Based Study.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pedal acceleration time as a diagnostic and prognostic tool in peripheral artery disease: systematic review and meta-analysis.BMC medical imaging · 2026Pooled it
- Trends and racial-geographic disparities in mortality among US older adults with peripheral artery disease, 1999 to 2020.Proceedings (Baylor University. Medical Center) · 2026Article
- A Review of Peripheral Vascular Intervention Technologies.Journal of clinical medicine · 2026Review
- Smoking Behavior and Major Cardiovascular and Limb Events in Patients With Peripheral Artery Disease.JAMA network open · 2026Article
- Associations between estimated glucose disposal rate and peripheral artery disease: evidence from the UK Biobank and NHANES.Nutrition & metabolism · 2026Article
- Cardiovascular Impact of Endovascular Revascularization in Chronic Limb-Threatening Ischemia Versus Claudication: A Contemporary Real-World Analysis.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Mechanically Robust Biodegradable Stents With Theragenerative Vascular Responses via Combined 3D Printing and Janus Nanoengineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Article
- Comprehensive evaluation of triglyceride glucose index-a body shape index (TyG-ABSI) for incident peripheral artery disease: data-driven phenotyping and machine learning-based risk prediction in the UK Biobank.Cardiovascular diabetology · 2026Article
- Retrospective Cohort Study Analysing Response to Supervised Exercise Therapy and Subsequent Revascularization in Patients with Intermittent Claudication.Journal of clinical medicine · 2026Article
- Efficacy and safety of external phytotherapy in diabetic foot ulcers: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2026Review
- Global Burden, Attributable Risk Factors, and Future Projections of Lower Extremity Peripheral Arterial Disease Among Postmenopausal Women.International journal of women's health · 2026Article
- Five-Year Outcomes of Paclitaxel-Coated Balloons in Patients with Diabetes from the BIOLUX P-III Single-Arm Study.Vascular health and risk management · 2026Article
- Spooky action at a distance: neuromodulation, physiologic distress signals, and limb preservation.Burns & trauma · 2026Review
- Integrative transcriptomics and human tibial artery validation identifyJVS-vascular science · 2026Article
- Forecasting the global burden of peripheral artery disease: implications for wound healing and healthcare systems.Burns & trauma · 2026Article
- Burden trends and disparities of metabolic risk-attributable peripheral arterial disease in China (1990-2035): a comparative analysis with G20 countries.International journal of public health · 2026Article
- The Association of Diabetes and Atherosclerosis: Understanding the Molecular Mechanism of the Double Burden.Current medicinal chemistry · 2026Review
- Diabetes, Obesity, and the Metabolic Drivers of Peripheral Artery Disease: Lessons from Recent Forecasts.Vascular health and risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular disease is the leading cause of death worldwide. Predicting the burden of vascular disease and identifying modifiable key risk factors are critical for developing effective prevention strategies. This study aimed to project the global and regional burden of peripheral artery disease (PAD) from 2021 to 2050, with a specific focus on the impact of modifiable key risk factors and the potential benefits of their management. Compared to the 2021 Global Burden of Disease Study (GBD 2021), the number of PAD cases worldwide is projected to increase by 220% by 2050, reaching a staggering 360 million (95% uncertainty interval, 270 to 450). Age-standardized mortality is expected to double, while disability-adjusted life years (DALYs) are forecasted to rise from 19.7 to 33.1 per 100,000. Among individuals aged ≥65 years, PAD prevalence is projected to surge to 21.7% in women and 14.8% in men. Moreover, over 50% of PAD cases are expected to occur in low- and middle-income countries (LMICs). Metabolic diseases are anticipated to be the primary drivers of the rising PAD burden, with diabetes playing a key role in increasing PAD prevalence and severity. By effectively managing metabolic risk factors, age-standardized prevalence could be reduced by 36%, mortality by 17%, and DALYs by 10%. As metabolic risks, particularly diabetes, continue to rise alongside population aging, the global PAD burden is expected to increase substantially, especially in LMICs. Importantly, proactive metabolic risk management strategies have the potential to markedly alleviate the burden of vascular disease and reduce the growing geographic health disparities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.